Irish Dermatologists' Experience with Janus Kinase Inhibitors in Alopecia Areata

    June 2025 in “ British Journal of Dermatology ”
    Cristina Grechin, Marina O’Kane
    From the encyclopedia
    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Studysummary This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    A study involving 21 Irish dermatologists (17% response rate) explored their experiences with Janus kinase inhibitors (JAKis) in treating alopecia areata (AA). The majority (90%) had used JAKis, primarily baricitinib (81%), and assessed treatment response at 3 or 6 months. Factors influencing JAKi use included the patient's Dermatology Life Quality Index, age, comorbidities, literature on long-term effects, and cost reimbursement. There is significant variability in ongoing treatment practices, with 95% of respondents highlighting the urgent need for guidelines on JAKi use in AA due to the lack of clear literature and global guidelines.
    Discuss this study in the Community →